A study showed that recombinant HP-NAP promotes the maturation of DC-based vaccine loaded with lysates from melanoma cells and this vaccine was able to enhance the activation, proliferation, and cytotoxic response of melanoma tumor cell-specific T cells, supporting the role of HP-NAP as an adjuvant of a DC-based vaccine to enhance anti-melanoma responses [87]. This evidence concerns the gene CTNNBL1 and neoplasm.